Podcast 23 Feb 2024
Precision neuromedicine: A new dawn for neurological disorders
This week on our podcast, explore how precision neuromedicine is reshaping neurological care with Rapport Therapeutics.
Epilepsy
- Latest Posts
In Depth 31 Jan 2024
New epilepsy drugs: what is in the pipeline?
Find out about the new epilepsy drugs currently in the pipeline, as resistance to current AEDs underscores the need for new treatments.
News and Trends 18 May 2023
New epilepsy study could lead to new treatment options
The mechanisms underlying the pathogenesis of epilepsy, a neurological disorder characterized by excessive electrical activity in the brain, remain unknown. Now, using a novel radiotracer, researchers from Japan have been able to offer insight into the role of AMPAR trafficking in epileptogenesis. The radio tracer is [11C]K-2, the first technology to visualize and quantify α-amino-3-hydroxy-5-methyl-4-isoxazole […]
News and Trends 10 Feb 2023
Europe approves childhood epilepsy treatment
UCB’s FINTEPLA (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. The approval by the European Commission (EC) was based on safety and efficacy data from a […]
News and Trends 8 Dec 2022
Metrion and KCNC1 Foundation announce collaboration to identify therapeutic
Metrion Biosciences Limited, and The KCNC1 Foundation are to collaborate to try and find a therapeutic for children. The KCNC1 Foundation is a not-for-profit organization focused on the development of a treatment for an ultra-rare genetic disorder. Variants of the KCNC1 gene impact Kv3.1 potassium channel function, resulting in neurodevelopmental disorders, which can include progressive […]
News and Trends 7 Dec 2022
Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years
Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment of Neuraxpharm Netherlands, increasing its presences from two to 20 countries in six years. The company says the expansion into the Dutch market allows it to continue on its pathway to become the number one […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 23 Nov 2022
UCB publishes Lennox-Gastaut syndrome study data
UCB has announced the publication of long-term open-label extension (OLE) study results of FINTEPLA (fenfluramine) CIV in the journal Epilepsia. Long-term efficacy and safety findings showed that FINTEPLA, when added to a patient’s current anti-epileptic treatment regimen for seizures associated with Lennox-Gastaut syndrome (LGS), was effective in reducing the frequency of multiple seizure types and […]
News and Trends 15 Nov 2022
Researchers awarded £2M to develop drugs to prevent epileptic seizures in children
Scientists at Aston University in the U.K. have started work on a project that will look for new drug treatments to prevent the onset of childhood epilepsy. The three-year Medical Research Council (MRC) funded project is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, partnered with Bristol […]
More News! 26 Oct 2022
Neuraxpharm to commercialize device giving early warning of epileptic seizures
A wearable medical device that can give an early warning of an epileptic seizure has been developed by medical device startup, mjn-neuro. Central nervous system (CNS) specialist Neuraxpharm Group entered the digital health market by signing a commercialization agreement with the developer for mjn-SERAS with exclusivity in Europe. With this agreement, Neuraxpharm increases its end-to-end […]
News and Trends 10 Aug 2022
Epilepsy drug accepted for review in Canada and Israel
SK Biopharmaceuticals, Co., Ltd. says Health Canada has accepted Paladin Labs Inc.’s filing of a new drug submission (NDS) for cenobamate as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. If Health Canada approves the NDS, Paladin Labs would be able to […]
News and Trends 1 Jun 2022
New treatment option available for Dravet syndrome
Global biopharma company UCB says the UK’s National Institute for Healthcare Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) for its FINTEPLA (fenfluramine) oral solution. FINTEPLA is used for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. […]
News and Trends 29 May 2020
Spanish Neurology Biotech Launches with €7.6M Series A
Accure Therapeutics, a neurology biotech targeting central nervous system (CNS) conditions such as multiple sclerosis and Parkinson’s disease, has launched in Barcelona with a Series A of €7.6M. Alta Life Sciences, a life science venture capital firm based in the same city, and the Spanish governmental institution The Centre for Technological and Industrial Development funded […]
ADVERTISEMENT